About 79% of digital health leaders said their companies are pursuing new investment capital in the next year, according to a recent survey from Summit Health Advisors. The post Top Priorities and Challenges for Digital Health Leaders in 2025: 5 Key Insights appeared first on MedCity News.
Many healthcare AI developers lack access to real-world data. To address this, Atropos Health is allowing AI developers to train and deploy their models using its real-world evidence network. The federated healthcare data network consists of more than 300 million patient records gathered from EHRs, claims data and patient registries. The post AI Developers Need…
Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions. The post FDA Wraps Up 2024 Handing Out Several Notable Regulatory Decisions appeared first on MedCity News.
Pfizer is walking away from partner Sangamo Therapeutics ahead of expected regulatory submissions for the hemophilia A gene therapy they co-developed. Cash-strapped Sangamo said it is now looking for a new partner for the program. The post Pfizer Ends Sangamo Alliance With Gene Therapy for Hemophilia on Cusp of FDA Filing appeared first on MedCity…
Amid the chaos and confusion of healthcare IT in our age of AI, a triage concept may be the best guide for organizations fighting to stray strong and capable in 2025 and beyond. The post Healthcare IT in 2025: Triage for the Age of AI appeared first on MedCity News.
Medicaid and CHIP facilitate necessary access to oral health services, which helps to bridge the gap in dental care for children from low- and moderate-income families. By providing coverage, it ensures that socioeconomic status does not hinder a child’s ability to receive necessary dental services. The post The Evolving Landscape of Medicaid and CHIP: Implications…
December saw a slew of executive hires, promotions, exits and layoffs across the healthcare industry. For example, companies like Humana and Mayo Clinic hired new C-suite leaders, organizations including Atlantic Health System and Amwell are saying goodbye to key executives, and firms like CVS Health and Optum announced rounds of job cuts. The post Healthcare…
One Phase 3 test of Auvelity met its main goal in Alzheimer’s agitation while the drug’s other pivotal trial showed numerical improvement that fell short of statistical significance. Axsome Therapeutics aims to offer an alternative to Rexulti, a Lundbeck and Otsuka Pharmaceutical product that is the only FDA-approved Alzheimer’s agitation drug. The post Axsome Aims…
The Uno Savings Guide is a free resource that helps people check their eligibility for financial benefit programs, like Medicaid, Medicare Savings Programs and SNAP. The post Uno Health Unveils Tool to Help Americans Check Eligibility for Financial Benefits appeared first on MedCity News.
Opdivo Qvantig, administered by injection in less than five minutes, is now FDA approved for solid tumor indications covered by Opdivo, a 30-minute intravenous infusion. The new product will help Bristol Myers Squibb compete with biosimilars as Opdivo faces looming patent expiration. The post Bristol Myers Squibb Wins FDA Nod for Injectable Version of Blockbuster…